These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17219738)

  • 1. Nevirapine-associated hepatotoxicity in virologically suppressed patients--role of gender and CD4+ cell counts.
    Mallolas J
    AIDS Rev; 2006; 8(4):238-9. PubMed ID: 17219738
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
    De Lazzari E; León A; Arnaiz JA; Martinez E; Knobel H; Negredo E; Clotet B; Montaner J; Storfer S; Asenjo MA; Mallolas J; Miró JM; Gatell JM
    HIV Med; 2008 Apr; 9(4):221-6. PubMed ID: 18366445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety issues about nevirapine administration in HIV-infected pregnant women.
    Manfredi R; Calza L
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):365-8. PubMed ID: 17592340
    [No Abstract]   [Full Text] [Related]  

  • 4. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 5. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl.
    Manfredi R; Calza L
    AIDS; 2006 Nov; 20(17):2233-6. PubMed ID: 17086066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
    Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study.
    Antela A; Ocampo A; Gómez R; López MJ; Mariño A; Losada E; Rodríguez R; Fernández R; Corredoira JC; Naval G; Rodríguez A; Miralles C; Prieto A; Gevihga Galician HIV Study Group
    HIV Clin Trials; 2010; 11(1):11-7. PubMed ID: 20400407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
    Kondo W; Carraro EA; Prandel E; Dias JM; Perini J; Macedo RL; Cornelsen TC; Sbalquiero R; Sasaki Md
    Braz J Infect Dis; 2007 Dec; 11(6):544-8. PubMed ID: 18327464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.
    Knobel H; Guelar A; Montero M; Carmona A; Luque S; Berenguer N; González A
    HIV Med; 2008 Jan; 9(1):14-8. PubMed ID: 18199168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
    Shahar E; Krivoy N; Weltfriend S; Pollack S
    Jpn J Infect Dis; 2004 Oct; 57(5):212-3. PubMed ID: 15507779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity associated with nevirapine use.
    Baylor MS; Johann-Liang R
    J Acquir Immune Defic Syndr; 2004 Apr; 35(5):538-9. PubMed ID: 15021321
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
    Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
    Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():14-5. PubMed ID: 12043064
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
    Bundow D; Rosoff L; Aboulafia DM
    AIDS Read; 2001 Nov; 11(11):577-80. PubMed ID: 11789021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
    Lyons F; Hopkins S; Kelleher B; McGeary A; Sheehan G; Geoghegan J; Bergin C; Mulcahy FM; McCormick PA
    HIV Med; 2006 May; 7(4):255-60. PubMed ID: 16630038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
    Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk for immune-mediated liver reactions by nevirapine revisited.
    Medrano J; Barreiro P; Tuma P; Vispo E; Labarga P; Blanco F; Soriano V
    AIDS Rev; 2008; 10(2):110-5. PubMed ID: 18615121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintaining a low viral load with Nevirapine?
    TreatmentUpdate; 1998 Dec; 10(10):3-4. PubMed ID: 11366017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
    Kumarasamy N; Venkatesh KK; Devaleenal B; Palanivel V; Cecelia AJ; Muthu S; Yepthomi T; Mayer KH; Flanigan T
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):598-600. PubMed ID: 17704685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.